Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2016

View Archived Issues

Otsuka tuberculosis candidate granted U.S. orphan drug designation

DynPort Vaccine Company plague vaccine granted FDA orphan drug status

Neutralizing human MAbs protect against infection and maternal-fetal transmission of ZIKV in vivo

Ortho-McNeil-Janssen Pharmaceuticals and KU Leuven patent dengue viral replication inhibitors

Roche and Genentech disclose ERalpha ligands

Cardiome Pharma launches Xydalba in U.K.

FDA accepts durvalumab BLA for urothelial cancer

GlaxoSmithKline describes KMO inhibitors

3D microtissue engineering used to generate hypertrophic cardiomyopathy cardiomyocytes

Soligenix reports long-term follow-up data from phase II trial of SGX-942 for oral mucositis

New U.K. alliance established to accelerate development of treatments for arthritis

SNPs in BDNF and GSK-3beta may be associated with bipolar disorder

AstraZeneca initiates phase I study of abediterol and AZD-7594

E2F4 activation shows promise for SCI recovery

Phase III trials show no benefit in adding Fovista to Lucentis for wet AMD

New MGL inhibitor shows promise for the treatment of pain

Valeant Pharmaceuticals reports positive results from phase III study of IDP-118

Synergy reports results from first phase III trial of plecanatide for IBS-C

BioInvent terminates phase II study of BI-505 in multiple myeloma

New phase I trial explores use of PGT-121 for HIV prevention and therapy

Seattle Genetics initiates phase I trial of SGN-CD352A in relapsed or refractory multiple myeloma

Popular Stories

University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Beijing Innocare Pharma Tech discloses new GSPT1 degradation inducers
BioWorld Science
Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic...